China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a significant multi-dimension tie-up that builds upon their existing collaboration in product distribution, access, and retail. This alliance, which began in April 2023, initially focused on the import and distribution of Xerava (eravacycline) in mainland China.
Eravacycline: A New Antibiotic for Multidrug-Resistant Infections
Eravacycline is a novel, fully synthetic, fluorocycline intravenous antibiotic developed for treating infections caused by a range of susceptible gram-positive, gram-negative, and anaerobic pathogens, including those that are multidrug-resistant (MDR). The product has received approval for the treatment of complicated intra-abdominal infections in the US, EU, GB, Singapore, and mainland China, with a review for cIAI underway in the Taiwan region. Eravacycline was licensed from Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of Innoviva, Inc., and commercialization in China commenced late last month.
Upcoming Launches and Therapies
Everest Medicines anticipates the launch of three additional novel drugs within the next 18 months in China. These include Nefecon for IgA nephropathy (IgAN), cefepime/taniborbactam for the treatment of complicated urinary tract infections, and etrasimod, a drug for autoimmune diseases. This expansion highlights Everest Medicines’ commitment to bringing innovative therapies to the Chinese market and enhancing patient access to advanced treatments.-Fineline Info & Tech
